113 related articles for article (PubMed ID: 3839157)
1. The Eastern Cooperative Oncology Group experience with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer.
Falkson G; Gelman RS; Tormey DC; Cummings FJ; Carbone PP; Falkson HC
Cancer; 1985 Jul; 56(2):219-24. PubMed ID: 3839157
[TBL] [Abstract][Full Text] [Related]
2. Treatment of metastatic breast cancer in premenopausal women using CAF with or without oophorectomy: an Eastern Cooperative Oncology Group Study.
Falkson G; Gelman RS; Tormey DC; Falkson CI; Wolter JM; Cummings FJ
J Clin Oncol; 1987 Jun; 5(6):881-9. PubMed ID: 3585444
[TBL] [Abstract][Full Text] [Related]
3. Ten-year follow-up study of premenopausal women with metastatic breast cancer: an Eastern Cooperative Oncology Group study.
Falkson G; Holcroft C; Gelman RS; Tormey DC; Wolter JM; Cummings FJ
J Clin Oncol; 1995 Jun; 13(6):1453-8. PubMed ID: 7751892
[TBL] [Abstract][Full Text] [Related]
4. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma.
Bennett JM; Muss HB; Doroshow JH; Wolff S; Krementz ET; Cartwright K; Dukart G; Reisman A; Schoch I
J Clin Oncol; 1988 Oct; 6(10):1611-20. PubMed ID: 3049953
[TBL] [Abstract][Full Text] [Related]
5. Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study.
Sledge GW; Hu P; Falkson G; Tormey D; Abeloff M
J Clin Oncol; 2000 Jan; 18(2):262-6. PubMed ID: 10637238
[TBL] [Abstract][Full Text] [Related]
6. Phase III study of standard combination versus rotating regimen of induction chemotherapy in patients with hormone insensitive metastatic breast cancer: an Eastern Cooperative Oncology Group Intergroup Study (E3185).
Pandya KJ; Hu P; Osborne CK; Falkson G; Tormey DC;
Am J Clin Oncol; 2007 Apr; 30(2):113-25. PubMed ID: 17414459
[TBL] [Abstract][Full Text] [Related]
7. Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281.
Aisner J; Cirrincione C; Perloff M; Perry M; Budman D; Abrams J; Panasci L; Muss H; Citron M; Holland J
J Clin Oncol; 1995 Jun; 13(6):1443-52. PubMed ID: 7751891
[TBL] [Abstract][Full Text] [Related]
8. Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140.
Parnes HL; Cirrincione C; Aisner J; Berry DA; Allen SL; Abrams J; Chuang E; Cooper MR; Perry MC; Duggan DB; Szatrowski TP; Henderson IC; Norton L;
J Clin Oncol; 2003 May; 21(9):1819-24. PubMed ID: 12721259
[TBL] [Abstract][Full Text] [Related]
9. [Results of clinical trials with a CMitF (cyclophosphamide, mitoxantrone, and 5-fluorouracil) regimen versus a CAF (cyclophosphamide, adriamycin, and 5-fluorouracil) regimen in advanced/relapsed breast cancer].
Taguchi T; Sakai K; Terasawa T; Wada H
Gan To Kagaku Ryoho; 1986 Sep; 13(9):2820-8. PubMed ID: 3530139
[TBL] [Abstract][Full Text] [Related]
10. [Combination chemotherapy of cyclophosphamide adriamycin and 5-fluorouracil (CAF) in advanced and recurrent breast cancer].
Abe O; Izuo M; Enomoto K; Kubo K; Koyama H; Sakai K; Terasawa T; Tominaga T; Nomura Y
Gan To Kagaku Ryoho; 1982 May; 9(5):866-73. PubMed ID: 7184431
[TBL] [Abstract][Full Text] [Related]
11. Cyclophosphamide, doxorubicin and fluorouracil (CAF) plus depo-buserelin in the treatment of premenopausal women with metastatic breast cancer.
Falkson CI; Falkson HC; Falkson G
Ann Oncol; 1992 Dec; 3(10):849-53. PubMed ID: 1286048
[TBL] [Abstract][Full Text] [Related]
12. Chemohormonal therapy in advanced carcinoma of the breast: Cancer and Leukemia Group B protocol 8081.
Perry MC; Kardinal CG; Korzun AH; Ginsberg SJ; Raich PC; Holland JF; Ellison RR; Kopel S; Schilling A; Aisner J
J Clin Oncol; 1987 Oct; 5(10):1534-45. PubMed ID: 3655856
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An Eastern Cooperative Oncology Group trial.
Tormey DC; Gray R; Gilchrist K; Grage T; Carbone PP; Wolter J; Woll JE; Cummings FJ
Cancer; 1990 Jan; 65(2):200-6. PubMed ID: 2403834
[TBL] [Abstract][Full Text] [Related]
14. Chemoendocrine therapy vs chemotherapy alone for advanced breast cancer in postmenopausal women: preliminary report of a randomized study.
Kardinal CG; Perry MC; Weinberg V; Wood W; Ginsberg S; Raju RN
Breast Cancer Res Treat; 1983; 3(4):365-71. PubMed ID: 6365209
[TBL] [Abstract][Full Text] [Related]
15. Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicin.
Stewart DJ; Evans WK; Shepherd FA; Wilson KS; Pritchard KI; Trudeau ME; Wilson JJ; Martz K
J Clin Oncol; 1997 May; 15(5):1897-905. PubMed ID: 9164200
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial.
Jassem J; Pieńkowski T; Płuzańska A; Jelic S; Gorbunova V; Mrsic-Krmpotic Z; Berzins J; Nagykalnai T; Wigler N; Renard J; Munier S; Weil C;
J Clin Oncol; 2001 Mar; 19(6):1707-15. PubMed ID: 11251000
[TBL] [Abstract][Full Text] [Related]
17. A phase II evaluation of combination chemotherapy plus aminoglutethimide in women with metastatic or recurrent breast carcinoma. An Eastern Cooperative Oncology Group Pilot Study.
Grem JL; Falkson G; Love RR; Tormey DC
Am J Clin Oncol; 1988 Oct; 11(5):528-34. PubMed ID: 3177253
[TBL] [Abstract][Full Text] [Related]
18. A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer.
Bennett JM; Byrne P; Desai A; White C; DeConti R; Vogel C; Krementz E; Muggia F; Doroshow J; Plotkin D
Invest New Drugs; 1985; 3(2):179-85. PubMed ID: 3894279
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant CMFP versus CMFP plus tamoxifen versus observation alone in postmenopausal, node-positive breast cancer patients: three-year results of an Eastern Cooperative Oncology Group study.
Taylor SG; Kalish LA; Olson JE; Cummings F; Bennett JM; Falkson G; Tormey DC; Carbone PP
J Clin Oncol; 1985 Feb; 3(2):144-54. PubMed ID: 3881561
[TBL] [Abstract][Full Text] [Related]
20. Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors.
Cummings FJ; Gelman R; Horton J
J Clin Oncol; 1985 Jul; 3(7):932-40. PubMed ID: 3894587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
